Immunology News and Research

Latest Immunology News and Research

Gene playing crucial role in immune system balance identified

A team led by St. Jude researchers identified a gene pivotal for immune system balance. Ultimately, the discovery may aid efforts to tame allergies and asthma.

12 Apr 2010

Asthma-like symptoms in infants and toddlers is often RAD

Your child is wheezing. Your child must have asthma, right? Not always, says Julie Koehler, professor and chair of the Department of Pharmacy Practice in Butler University's College of Pharmacy and Health Sciences and clinical pharmacy specialist in family medicine at Clarian Health.

12 Apr 2010

Nationwide Asthma Screening Program to find people at risk

The American College of Allergy, Asthma and Immunology will help adults and children to find out if they are at risk for asthma through its Nationwide Asthma Screening Program. More than 200 screenings will take place across the country this year. Locate one near you on the calendar of screenings available at AllergyAndAsthmaRelief.org.

12 Apr 2010

Pollen overload in some parts of US, situation grim for asthmatics

Unusual cold seasons across US has lead to an all time high in pollen this season. Southeast is one of the worst affected with a yellow mist of pollen hanging around constantly. Normally a pollen count of 120 is considered high. This year it has risen up to 5,733 in Atlanta last week. This is the second-highest level on record, according to The Weather Channel. (The city's record - 6,013 on April 12, 1999.)

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

A*STAR announces fifth major collaboration with Italian research centres and universities

Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .

9 Apr 2010

AmericanEHR Partners Program introduced to help medical practitioners compare EHR systems

A collaboration developing a new Web site to help medical practitioners compare electronic health records systems was announced today by its founding partners, the American College of Physicians and Cientis Technologies.

9 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

New strategies to help allergy sufferers survive the winds of spring, summer

Every spring and summer, millions of Americans dread the trip to the park, the playground, or participating in any of the myriad activities that trigger outdoor allergy symptoms.

8 Apr 2010

Single vaccine for anthrax and plague: iBio confirms grant of rights

iBio, Inc. confirmed today the grant of rights to use iBio's proprietary technology, the iBioLaunch™ platform, in support of a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

Messenger substance plays significant role in viral diseases and reactions to infections

The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.

6 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

A scientist at Barrow Neurological Institute in Phoenix has been awarded a major grant from the Muscular Dystrophy Association to continue his groundbreaking work in the disease of myasthenia gravis.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Economic burden associated with HAE treatment: First-ever comprehensive examination

Dyax Corp. announced the publication of a first-ever comprehensive examination of the economic burden associated with the treatment of acute attacks and chronic management of hereditary angioedema (HAE). The results, published today in the Annals of Allergy, Asthma, and Immunology, bring to light the substantial direct and indirect medical costs of the disease on patients, payers and society. The economic study is one component of a larger survey-based Burden of Illness (BOI) study which assessed both the economic and humanistic burden of HAE.

5 Apr 2010

Immunology News and Research

Latest Immunology News and Research

Gene playing crucial role in immune system balance identified

Asthma-like symptoms in infants and toddlers is often RAD

Nationwide Asthma Screening Program to find people at risk

Pollen overload in some parts of US, situation grim for asthmatics

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

A*STAR announces fifth major collaboration with Italian research centres and universities

AmericanEHR Partners Program introduced to help medical practitioners compare EHR systems

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

New strategies to help allergy sufferers survive the winds of spring, summer

Single vaccine for anthrax and plague: iBio confirms grant of rights

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Women living in northeastern U.S. more likely to develop RA: Study

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Messenger substance plays significant role in viral diseases and reactions to infections

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Economic burden associated with HAE treatment: First-ever comprehensive examination

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech